On 12 March 2013, orphan designation (EU/3/13/1116) was granted by the European Commission to Glaxo Group Ltd, United Kingdom, for mepolizumab for the treatment of Churg-Strauss syndrome.
The sponsorship was transferred to GlaxoSmithKline Trading Services Limited, Ireland, in May 2018.
The sponsor’s address was updated in April 2020. In April 2020, GlaxoSmithKline Trading Services Limited changed name to GlaxoSmithKline (Ireland) Limited.
|Disease / condition||
Treatment of Churg-Strauss syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.